1. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗